Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Tirzepatide for the treatment of obstructive sleep apnea and obesity

Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC…. New England Journal of Medicine 2024

Document identifier
CEI-BR-069
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J
Title
Tirzepatide for the treatment of obstructive sleep apnea and obesity
Source
New England Journal of Medicine
Year
2024
Volume, issue, pages
391(13):1193–1205
Digital object identifier
10.1056/NEJMoa2404881
PubMed identifier
38912654
Record type
Journal article
Institute identifier
CEI-BR-069

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: TirzepatideCompound monograph
Synthesis: Tirzepatide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Tirzepatide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Tirzepatide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Tirzepatide in obstructive sleep apnoea with obesity: effect on the…Evidence synthesis
Synthesis: Tirzepatide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Tirzepatide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Tirzepatide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Tirzepatide in obstructive sleep apnoea with obesity: tolerability…Evidence synthesis
Synthesis: Tirzepatide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Tirzepatide in type 2 diabetes mellitus: durability of effectEvidence synthesis
11 citing documents.

§1.3Subject tags

tirzepatide osa SURMOUNT-OSA

Compound Evidence Institute · CEI-BR-069 · https://compoundevidence.com/bibliography/malhotra2024/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.